PRDM1 and lymphoma: (90) have demonstrated that the cellular target of the EBV-miRNA-BHRF1-2 is PRDM1, and that by inhibiting the PRDM1-mediated function and conferred a growth advantage to EBV-infected B cells, promoting lymphoma development.